Clinical Trials of Immune Checkpoint Inhibitors as First Line Therapy for Advanced NSCLC

Dr. Jack West summarizes the rationale for testing immune checkpoint inhibitors as a first line treatment for patients with advanced NSCLC and highlights details of two trials testing this question.

November is Lung Cancer Awareness Month. What are you grateful for?

Watch, read, and then share your own stories of empowerment in our online forum. Your story may inspire others.

Get more information about the IMpower-110 Trial and CheckMate-227 Trial.

Check out more LCAM videos & posts here.

GRACE is supported by contributions from our membership. Be a part of the solution. Donate Today!

This content is for personal use only and is subject to the GRACE Disclaimer terms.